|
|
Volumn 164, Issue SUPPL. 1, 2011, Pages 35-38
|
|
What does the future hold for clinical studies in vasculitis?
|
|
Author keywords
Aetiology; Cyclophosphamide; Future; Methotrexate; Rituximab
|
|
Indexed keywords
AZATHIOPRINE;
CYCLOPHOSPHAMIDE;
GLUCOCORTICOID;
INTERLEUKIN 5;
METHOTREXATE;
NEUTROPHIL CYTOPLASMIC ANTIBODY;
RITUXIMAB;
AORTA ARCH SYNDROME;
ARTICLE;
AUTOIMMUNITY;
CHURG STRAUSS SYNDROME;
COST BENEFIT ANALYSIS;
DISEASE SEVERITY;
DRUG EFFICACY;
DRUG SUBSTITUTION;
DRUG USE;
DRUG WITHDRAWAL;
FOLLOW UP;
GRANULOMATOSIS;
GRANULOMATOSIS WITH POLYANGIITIS;
HUMAN;
MAINTENANCE THERAPY;
MICROSCOPIC POLYANGIITIS;
PHENOTYPE;
PRIORITY JOURNAL;
RELAPSE;
REMISSION;
RISK BENEFIT ANALYSIS;
TREATMENT DURATION;
VASCULITIS;
WEGENER GRANULOMATOSIS;
ANTIBODIES, MONOCLONAL, MURINE-DERIVED;
AZATHIOPRINE;
CYCLOPHOSPHAMIDE;
GLUCOCORTICOIDS;
HISTORY, 20TH CENTURY;
HISTORY, 21ST CENTURY;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
INTERFERON-GAMMA;
INTERLEUKIN-5;
METHOTREXATE;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
SEVERITY OF ILLNESS INDEX;
TREATMENT OUTCOME;
VASCULITIS;
|
|
EID: 79953147528
PISSN: 00099104
EISSN: 13652249
Source Type: Journal
DOI: 10.1111/j.1365-2249.2011.04365.x Document Type: Article |
|
Times cited : (7)
|
|
References (0)
|
